Preclinical development and characterisation of PP353, a formulation of linezolid for intradiscal administration.

ABSTRACT:

Introduction

Bacterial infection of the intervertebral disc can lead to vertebral endplate edema known as Modic changes, with associated chronic low back pain. Oral antimicrobial therapy has shown efficacy but relies on prolonged dosing and may not be optimal in terms of patient outcome, side effects, or antibiotic stewardship. There is no antibiotic formulation approved for intradiscal administration. Here, we describe the development and preclinical characterization of a formulation of linezolid, a suspension of 50 mg/mL micronized powder, for intradiscal administration.

Methods

Micronization, particle size analysis, Franz cell diffusion assays, ex vivo bioassay, and estimates of gelling temperature were used to optimize the composition and properties of the formulation. P

SUBMITTER: Hagger G 

PROVIDER: S-EPMC11561648 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature